» Articles » PMID: 18207658

External Beam Boost for Cancer of the Cervix Uteri when Intracavitary Therapy Cannot Be Performed

Overview
Specialties Oncology
Radiology
Date 2008 Jan 22
PMID 18207658
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To assess the outcome of patients treated with radical radiotherapy for cervical cancer who received an external beam boost, in place of intracavitary brachytherapy (ICT), after irradiation to the whole pelvis.

Methods And Materials: Case notes were reviewed for all patients treated in this way in a single center between 1996 and 2004. Patient and tumor details, the reasons why ICT was not possible, and treatment outcome were documented.

Results: Forty-four patients were identified. The mean age was 56.4 years (range, 26-88 years). Clinical International Federation of Gynecology and Obstetrics or radiologic stage for Stages I, II, III, and IV, respectively, was 16%, 48%, 27%, and 7%. A total radiation dose of 54-70 Gy was given (75% received > or =60 Gy). Reasons for ICT not being performed were technical limitations in 73%, comorbidity or isolation limitations in 23%, and patient choice in 4%. The median follow-up was 2.3 years. Recurrent disease was seen in 48%, with a median time to recurrence of 2.3 years. Central recurrence was seen in 16 of the 21 patients with recurrent disease. The 5-year overall survival rate was 49.3%. The 3-year cancer-specific survival rate by stage was 100%, 70%, and 42% for Stages I, II, and III, respectively. Late Grades 1 and 2 bowel, bladder, and vaginal toxicity were seen in 41%. Late Grade 3 toxicity was seen in 2%.

Conclusion: An external beam boost is a reasonable option after external beam radiotherapy to the pelvis when it is not possible to perform ICT.

Citing Articles

Cone-Beam Computed Tomography (CBCT)-Guided Adaptive Boost Radiotherapy for a Patient With Locally Advanced Cervical Cancer Ineligible for Brachytherapy.

Silberstein A, Schiff J, Beckert R, Zhao X, Laugeman E, Markovina S Cureus. 2024; 16(8):e66218.

PMID: 39233928 PMC: 11374352. DOI: 10.7759/cureus.66218.


Radiobiological and dosimetric comparison of 60Co versus 192Ir high-dose-rate intracavitary-interstitial brachytherapy for cervical cancer.

Wen A, Wang X, Wang B, Yan C, Luo J, Wang P Radiat Oncol. 2022; 17(1):206.

PMID: 36514118 PMC: 9749337. DOI: 10.1186/s13014-022-02170-8.


Stereotactic Body Radiotherapy Boost with the CyberKnife for Locally Advanced Cervical Cancer: Dosimetric Analysis and Potential Clinical Benefits.

Gao J, Xu B, Lin Y, Xu Z, Huang M, Li X Cancers (Basel). 2022; 14(20).

PMID: 36291951 PMC: 9600637. DOI: 10.3390/cancers14205166.


Comparative Analysis of 60Co and 192Ir Sources in High Dose Rate Brachytherapy for Cervical Cancer.

Wen A, Wang X, Wang B, Yan C, Luo J, Wang P Cancers (Basel). 2022; 14(19).

PMID: 36230672 PMC: 9563337. DOI: 10.3390/cancers14194749.


Adaptive Magnetic Resonance-Guided External Beam Radiation Therapy for Consolidation in Recurrent Cervical Cancer.

Felici F, Benkreira M, Lambaudie E, Fau P, Mailleux H, Ferre M Adv Radiat Oncol. 2022; 7(6):100999.

PMID: 36060635 PMC: 9429515. DOI: 10.1016/j.adro.2022.100999.